Tagrisso causes complaints over issue biopsy

Published: 2017-12-15 16:27:00
Updated: 2017-12-15 16:33:58

AstraZeneca Korea mentioned about the fact the Tagrisso’s(generic name: osimertinib) health insurance benefits will only be accepted only if a tissue biopsy is positive.

Tagrisso is a novel drug which overcame EGFR-targeted therapies’ resistance for the world’s first time in the non-small cell l...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.